Research and Markets has announced the addition of the "Benign Prostatic Hyperplasia Pipeline Highlights - 2017" drug pipelines to their offering.

This report, Benign Prostatic Hyperplasia Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Benign Prostatic Hyperplasia market. It covers emerging therapies for Benign Prostatic Hyperplasia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Benign Prostatic Hyperplasia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Benign Prostatic Hyperplasia pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Benign Prostatic Hyperplasia pipeline products by the company.

Short-term Launch Highlights:

Find out which Benign Prostatic Hyperplasia pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Benign Prostatic Hyperplasia Pipeline by Stages

2. Benign Prostatic Hyperplasia Pipeline by Drug Class

3. Benign Prostatic Hyperplasia Pipeline by Company

4. Benign Prostatic Hyperplasia Phase 3 Clinical Trial Insights

5. Benign Prostatic Hyperplasia Phase 2 Clinical Trial Insights

6. Benign Prostatic Hyperplasia Phase 1 Clinical Trial Insights

7. Benign Prostatic Hyperplasia Preclinical Research Insights

8. Benign Prostatic Hyperplasia Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/ghxfdx/benign_prostatic